Navigation Links
China's Type 2 Diabetes Drug Market Will More than Triple by 2012
Date:5/28/2008

New Entries to China Drug Market to Garner More Than $270 Million in

Combined Sales, According to a New Report by Decision Resources

WALTHAM, Mass., May 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Chinese type 2 diabetes drug market will more than triple by 2012. According to the new Emerging Markets report entitled Type 2 Diabetes in China, this growth will be fueled by increased access to health insurance, greater patient spending power and more aggressive treatment practice, leading to increased usage of newer agents such as the insulin analogues. Additionally, the number of prevalent cases of type 2 diabetes in China is among the highest in the world -- 62.5 million cases in 2007 -- a number that rivals that of the United States, Europe and Japan combined (48.5 million cases). The high prevalence rate in China reflects an aging population and urbanization-associated risk factors, such as diet and lack of physical activities.

"The Chinese government and medical associations are promoting guidelines published by the American Diabetes Association, the World Health Organization and the Chinese Society of Diabetes," said Victor Li, Ph.D., analyst at Decision Resources. "All guidelines advocate earlier and more-aggressive interventions in type 2 diabetes patients. We forecast that the patient population treated with polypharmacy will nearly double between 2007 and 2012."

The report also finds that three new type 2 diabetes agents with novel mechanisms -- Eli Lilly/Amylin's Byetta, Merck's Januvia and Novartis's Galvus -- are expected to launch in China by 2012. The combined sales of these three agents will surpass $270 million by 2012. However, the high cost of many antidiabetic therapies, particularly Western-branded drugs, is a major barrier to effective management of type 2 diabetes in China. Patient ability to pay for medications influences physician prescribing habits, particularly prescription of newer drugs such as the peroxisome proliferator-activated receptor (PPAR)-gamma agonists and the insulin analogues, which are not reimbursed or are only partially reimbursed in some provinces.

About Emerging Markets - China

Emerging Markets - China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can accomplish the following:

-- More accurately assess the commercial opportunity for Western brands in

key pharmaceutical markets of China -- Beijing, Shanghai,

Guangzhou -- and in the high-growth second-tier markets of Tianjin,

Wuhan, Nanjing, Hangzhou, and Jinan.

-- Understand the physician treatment patterns and drivers of choice in

key first- and second-tier cities based on primary research.

-- Gain a clear perspective of the Chinese five-year market forecast at

the drug level, broken out by urban and rural areas, and by sales from

multinational and Chinese-based companies.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perot Systems and ChinaSoft to Pursue Chinese Healthcare Opportunities
2. New insights in diagnosing diabetes may help the millions who are undiagnosed
3. Rhinestone Cure Sets the Glitz to Benefit Diabetes at Hotel Indigo
4. New Antioxidant Drug Shows Promise Against Diabetes
5. Lifestyle Changes Can Keep Diabetes at Bay for 14 Years
6. Anti-rejection drug may increase risk of diabetes after kidney transplant
7. Study: Doctors not always sure when to treat BP in people with diabetes
8. Study: Doctors Not Always Sure When to Treat Blood Pressure in People With Diabetes
9. Seattle Laces Up To Beat the Bridge and Diabetes
10. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
11. American Diabetes Wholesale Launches Affiliate Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... LAS VEGAS , June 26, 2016 ... movement to value-based care operating models within the health ... that enable greater financial efficiency , Deloitte offers ... address the key business issues impacting efficient cost optimization: ... alignment , These services facilitate better outcomes and ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
Breaking Medicine Technology: